• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Theravance Biopharma Inc.

    11/12/25 9:02:50 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TBPH alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001256230
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    THERAVANCE BIOPHARMA, INC.
    SEC File Number
    001-36033
    Address of Issuer
    901 Gateway Boulevard
    South San Francisco
    CALIFORNIA
    94080
    Phone
    650-808-6000
    Name of Person for Whose Account the Securities are To Be Sold
    ERAN BROSHY
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    45000809250.005036129611/11/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common04/30/2019Restricted StockIssuerCheckbox not checked468504/30/2019Not Applicable
    Common04/26/2023Restricted StockIssuerCheckbox not checked985204/26/2023Not Applicable
    Common11/11/2025Stock Option ExerciseIssuerCheckbox not checked1400011/11/2025Cash
    Common04/27/2021Restricted StockIssuerCheckbox not checked663504/27/2021Not Applicable
    Common04/26/2022Restricted StockIssuerCheckbox not checked982804/26/2022Not Applicable

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Sales that were executed on November 11, 2025 are being reported on this Form 144 filed on November 12, 2025 given the EDGAR system was not accepting filings on November 11, 2025 in observance of the federal holiday.
    Date of Notice
    11/11/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    06/14/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Eran Broshy

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $TBPH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TBPH

    DatePrice TargetRatingAnalyst
    9/12/2025$28.00Buy
    B. Riley Securities
    8/6/2024$15.00 → $10.00Outperform → Market Perform
    Leerink Partners
    4/12/2024$21.00Buy
    BTIG Research
    1/8/2024Outperform → In-line
    Evercore ISI
    5/23/2022$12.00Outperform
    SVB Leerink
    3/2/2022$10.00 → $11.00Underweight
    Morgan Stanley
    2/24/2022$8.00 → $12.00Buy
    HC Wainwright & Co.
    11/5/2021$7.00 → $12.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $TBPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Winningham Rick E gifted 9,900 units of Ordinary Shares, received a gift of 9,900 units of Ordinary Shares and covered exercise/tax liability with 56,817 units of Ordinary Shares, decreasing direct ownership by 4% to 1,651,069 units (SEC Form 4)

    4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

    11/21/25 7:10:33 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Broshy Eran sold $809,250 worth of Ordinary Shares (45,000 units at $17.98), decreasing direct ownership by 34% to 60,204 units (SEC Form 4)

    4/A - Theravance Biopharma, Inc. (0001583107) (Issuer)

    11/14/25 6:00:16 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Broshy Eran sold $1,068,250 worth of Ordinary Shares (59,000 units at $18.11), decreasing direct ownership by 49% to 46,204 units (SEC Form 4)

    4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

    11/13/25 9:00:16 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TBPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

    DUBLIN, Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here. The event will feature Horacio Kaufmann, MD (Dysautonomia Center, NYU Langone Health), who will join company management to discuss the unmet medical need for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA), a chronic, debilitating condition caused by autonomic dysfunction that is present in ~80% of

    11/20/25 11:00:00 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theravance Biopharma to Participate in Upcoming Investor Conferences

    DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that management will participate in the following investor conferences in December 2025: 8th Annual Evercore Healthcare ConferenceLocation: Coral Gables, FLFormat: Fireside ChatDate: Thursday, December 4, 2025Time: 8:20-8:40 AM ETWebcast Oppenheimer Movers in Rare Disease SummitLocation: New York, NYFormat: Panel Discussion - Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving CatalystsDate: Thursday, December 11, 2025Time: 2:15-2:45 PM ET Therav

    11/19/25 6:00:00 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year1, and achieved record brand profitabilityOpen-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine now complete; topline readout on track for Q1 2026Company to host an ampreloxetine focused virtual Key Opinion Leader (KOL) event for investors on December 8, 2025TRELEGY year-to-date sales on track to achieve $50 million milestone in 20252Strong balance sheet with $333 million in cash and no debtDUBLIN, Nov. 10, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today reported financial and operational results for the thi

    11/10/25 4:05:00 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TBPH
    SEC Filings

    View All

    SEC Form 10-Q filed by Theravance Biopharma Inc.

    10-Q - Theravance Biopharma, Inc. (0001583107) (Filer)

    11/12/25 4:16:06 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Theravance Biopharma Inc.

    144 - Theravance Biopharma, Inc. (0001583107) (Subject)

    11/12/25 9:02:50 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theravance Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Theravance Biopharma, Inc. (0001583107) (Filer)

    11/10/25 4:11:07 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TBPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Samaha Eli bought $7,798,440 worth of COM (999,800 units at $7.80) (SEC Form 4)

    4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

    8/9/24 6:02:35 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Samaha Eli bought $13,117,335 worth of COM (1,499,124 units at $8.75) (SEC Form 4)

    4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

    5/3/24 4:19:22 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TBPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Theravance Biopharma with a new price target

    B. Riley Securities initiated coverage of Theravance Biopharma with a rating of Buy and set a new price target of $28.00

    9/12/25 7:53:21 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theravance Biopharma downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Theravance Biopharma from Outperform to Market Perform and set a new price target of $10.00 from $15.00 previously

    8/6/24 8:00:45 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Theravance Biopharma with a new price target

    BTIG Research initiated coverage of Theravance Biopharma with a rating of Buy and set a new price target of $21.00

    4/12/24 7:40:50 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TBPH
    Leadership Updates

    Live Leadership Updates

    View All

    Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors

    Enters into Cooperation Agreement with Shareholder Irenic Capital Reaffirms Intention to Return All Excess Capital to Shareholders and MaximizeShareholder Value DUBLIN, Dec. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ:TBPH) today announced the appointment to its Board of Directors of Jeremy Grant, who serves as a Special Advisor to Irenic Capital Management LP ("Irenic"). With the addition of Mr. Grant, Theravance has appointed four new directors to the Board since 2020. "We are pleased to welcome Jeremy to the Theravance Board a

    12/21/23 5:00:00 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Irenic Welcomes the Appointment of a Shareholder Representative to Theravance Biopharma's Board of Directors

    Believes Jim Kelly of Weiss Asset Management Will Bring Important Ownership Mentality to the Boardroom Encourages the Board to Continue Taking Concrete Steps to Improve Capital Allocation, Enhance Corporate Governance and Review Strategic Alternatives Irenic Capital Management, LP (together with its affiliates, "Irenic" or "we"), a top shareholder of Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance" or the "Company"), today issued the following statement regarding the Company's appointment of Jim Kelly, Managing Director at Weiss Asset Management, to the Board of Directors (the "Board"): "Irenic welcomes the appointment of Jim Kelly to the Theravance Board. We respect and admire

    4/12/23 7:00:00 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors

    DUBLIN, April 11, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced the appointment of Jim Kelly, Managing Director at Weiss Asset Management, the Company's second largest shareholder, to its Board of Directors. With the appointment of Mr. Kelly, four new directors have joined the Company's Board of Directors since 2018 as part of its ongoing board refreshment process. "We are pleased to welcome Jim Kelly to the Theravance Board of Directors. Weiss Asset Management has been one of our largest shareholders si

    4/11/23 4:05:00 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TBPH
    Financials

    Live finance-specific insights

    View All

    Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

    DUBLIN, Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here. The event will feature Horacio Kaufmann, MD (Dysautonomia Center, NYU Langone Health), who will join company management to discuss the unmet medical need for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA), a chronic, debilitating condition caused by autonomic dysfunction that is present in ~80% of

    11/20/25 11:00:00 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    YUPELRI® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year1, and achieved record brand profitabilityOpen-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine now complete; topline readout on track for Q1 2026Company to host an ampreloxetine focused virtual Key Opinion Leader (KOL) event for investors on December 8, 2025TRELEGY year-to-date sales on track to achieve $50 million milestone in 20252Strong balance sheet with $333 million in cash and no debtDUBLIN, Nov. 10, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today reported financial and operational results for the thi

    11/10/25 4:05:00 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System

    Ampreloxetine clinical development program to be featured in four presentations at the upcoming International Symposium on The Autonomic Nervous SystemTopline results from the ongoing Phase 3 CYPRESS study of ampreloxetine anticipated in Q1 2026DUBLIN, Oct. 29, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) today announced that it will be participating at the 36th International Symposium on the Autonomic Nervous System, organized by the American Autonomic Society (AAS), taking place November 5-8, 2025, in Clearwater Beach, FL. The Company will have one platform presentation and three poster presentations on its clinical development program for ampreloxetine, a potential first-

    10/29/25 6:00:00 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TBPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Theravance Biopharma Inc.

    SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)

    11/14/24 9:53:41 AM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Theravance Biopharma Inc.

    SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)

    11/12/24 5:53:05 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Theravance Biopharma Inc.

    SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)

    11/4/24 3:33:04 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care